- About SAM
- Human medicines
- Marketing authorisation
- Drug information
- Clinical trials
- European Pharmacopoeia
- Pharmacovigilance
- Classification of medicinal products
- Statistics
- Manufacture, distribution, pharmacy
- Travelling with medicinal products
- The import and export of goods that require a special authorization
- Sending of medicinal products
- Advertising
- Marketing authorisation
- Veterinary medicines
- Department of Biologicals
- Blood handling
- Procurement and handling of cells, tissues and organs
- Biovigilance
- Application of cells, tissues and organs licence
- List of licensed procurers and handlers of cells, tissues and organs (tissue establishments)
- Legislation for procurement and handling cells, tissues and organs
- Special authorisation for import and export and notification of import and export of cells, tissues and organs
- Advanced therapies medicinal products
- The import and export of goods that require a special authorisation
- Legislation
- Supervision
- Laboratory
Ravimi Finlepsin turustamise lõpetamine
08.02.2021
Müügiloa hoidja Teva Pharma B.V. esindaja teatas järgmiste ravimite turustamise lõpetamisest:
- Finlepsin 400 mg toimeainet modifitseeritult vabastavad tabletid (toimeaine karbamasepiin). Saadaval on teine sama toimeainesisalduse, ravimvormi ja näidustusega ravim.
- Finlepsin 200 mg toimeainet modifitseeritult vabastavad tabletid (toimeaine karbamasepiin). Sama toimeaine ja näidustusega müügiloaga ravimi kättesaadavus on selgitamisel. Patsiendid peaksid ravi jätkamiseks pöörduma oma arsti poole.
- Finlepsin 200 mg tabletid (toimeaine karbamasepiin). Saadaval on teine sama toimeaine ja näidustusega ravim.
State Agency of Medicines
